G20 leaders urge to provide funds for Covid-19 vaccines, drugs, tests

The letter also called on G20 leaders to commit jointly to "a proportion of future stimulus" spending on the tools, which are particularly aimed at securing supplies for lower income countries

coronavirus test, testing cabin
A medic collects a swab sample of a man from a new swab testing cabin at Podar hospital in Worli during a nationwide lockdown in the wake of coronavirus pandemic, in Mumbai. Photo: PTI
Stephanie Nebehay | Reuters Geneva
2 min read Last Updated : Nov 20 2020 | 1:17 AM IST
G20 leaders must help close a funding gap to buy vaccines, drugs and tests to combat the COVID-19 pandemic, a letter from South Africa's president, Norway's prime minister, and the heads of the World Health Organization and European Commission said.

The letter, seen by Reuters, was sent ahead of the Group of 20's virtual summit at the weekend in Riyadh organised by Saudi Arabia, which currently holds the rotating presidency of the club of rich nations and big emerging powers.

"A commitment by G20 leaders at the G20 summit in Riyadh to invest substantially in the ACT (Access to COVID-19 Tools) Accelerator's immediate funding gap of US $4.5 billion will immediately save lives, lay the groundwork for mass procurement and delivery of COVID-19 tools around the world, and provide an exit strategy out of this global economic and human crisis," it said.

The letter also called on G20 leaders to commit jointly to "a proportion of future stimulus" spending on the tools, which are particularly aimed at securing supplies for lower income countries.The signatories were South African President Cyril Ramaphosa, Norway's Prime Minister Erna Solberg, World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus and Ursula von der Leyen, president of the European Commission.

"Engaging finance ministers now to actually raise all the money that we need, not only the urgent money needed for 2020 but actually make sure that we are fully funding the total work of the ACT Accelerator is so important," Dag Inge Ulstein, Norway's minister of international development, told Reuters in Geneva."It's the next weeks that will be very, very crucial," he said.

The facility set up by the WHO and the GAVI vaccine group has exceeded an interim target of raising more than $2 billion to buy and distribute COVID-19 shots for poorer countries, but said last week it still needed more.Roughly $28 billion is needed to fund fully the procurement and distribution of vaccines, drugs and tests, which von der Leyen said last week was equivalent to the same sum the transport sector and the global tourism sector lose in just two days of lockdown.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :G20 nationsCoronavirus VaccineCoronavirus Tests

Next Story